Cannabinoids are a group of chemicals in the marijuana plant and are said to have anti inflammatory effects in animal cells. Tetrahydrocannabinol (THC) is a psychoactive cannabinoid found with hundreds of others within the cannabis plant. Cannabinoid receptors (CB1 & CB2) are located in the endocannabinoid system (ECS) and these allow cannabinoids to work in the body.
This paper will look at the transient lower oesophageal sphincter relaxations (TLESR’s) in dogs and humans and what effect the CB1/CB2 receptor agonist tetrahydrocannabinol has on TLESR’s.
Here is the full scientific article if you wish to download it.
TLESR’s stands for transient lower esophageal sphincter relaxations. THC was administered in healthy dogs to see if CB1 receptor agonist (SR141716A) works to induce TLESR. It was found that a dose of THC did in fact inhibit TLESR and reduces the acid production rate. It also reduced the acid reflux in healthy human volunteers in the first hour after administration. Lower oesophageal sphincter pressure and swallowing were greatly reduced by the dose of THC.
After the 20 mg dose was administered, 9 of the dogs experienced nausea and vomiting, and this lead to finishing the study early. One of the other side effects included hypotension and tachycardia. THC significantly inhibited the increase in meal-induced TLESR’s and reduced out of the ordinary swallowing in both dogs and humans.
In humans, the dose of THC greatly reduced basal lower oesophageal sphincter pressure. The results of this study suggest that CB2 receptor in dogs and humans have a major role in activating the TLESR’s, and therefore unlocking cannabinoids potential to treat gastroesophageal reflux disease.
If you wish to use cannabis, or any product with THC as part of treatment for a medical condition, it’s important to research whether it’s legal in your state or country. Also seek medical advice.